Authors: Smaill, JB Showalter, HDH Zhou, HR Bridges, AJ McNamara, DJ Fry, DW Nelson, JM Sherwood, V Vincent, PW Roberts, BJ Elliott, WL Denny, WA

Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d]pyrimidines as soluble, irreversible inhibitors of theepidermal growth factor receptor, J MED CHEM, 44(3), 2001, pp. 429-440

Authors: Vincent, PW Bridges, AJ Dykes, DJ Fry, DW Leopold, WR Patmore, SJ Roberts, BJ Rose, S Sherwood, V Zhou, HR Elliott, WL

Citation: Pw. Vincent et al., Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts, CANC CHEMOT, 45(3), 2000, pp. 231-238

Authors: Smaill, JB Rewcastle, GW Bridges, AJ Zhou, HR Showalter, HDH Fry, DW Nelson, JM Sherwood, V Elliott, WL Vincent, PW DeJohn, DE Loo, JA Greis, KD Chan, OH Reyner, EL Lipka, E Denny, WA

Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions(vol 43, pg 1380, 2000), J MED CHEM, 43(16), 2000, pp. 3199-3199